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ABSTRACT 
We report a case of a meso-pancreatectomy performed on a pancreatic glucagonoma in a 58 years-
old woman. MP is a conservative surgical treatment consisting in a resection of the body of the 
pancreas with the aim of reducing postoperative hormone insufficiency. 
This approach is curative in benign or low-malignant neoplasm of the central part of the pancreas. 
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1. Introduction 
Glucagonoma is a neuroendocrine neoplasm of the pancreas accounting for less than 10% of the 
pancreatic neuroendocrine tumors; it was described for the first time by Becker in 1942. Patients 
with glucagonomas are classically 40–70 years of age with no significant preference for gender [1] 
and[2]. 
These pancreatic tumors usually originate in the body of the gland and they can be associated with 
other tumors in Multiple Endocrine Neoplasia syndrome 1 (MEN 1), but this association is rare and 
comprises no more than 3% of glucagonomas [3]. Diagnosis of Pancreatic Glucagonoma (PG) is 
established by bio-humoral characterization (glucagon, chromogranin A) and instrumental 
investigation (CT, EUS) but its presence is uncommon and symptoms are often vague; 
consequently the tumor may be relatively large when diagnosed. In 80% of cases PG is associated 
with diabetes and weight loss; the prognosis is unfavorable in 75% of cases. 
The optimal treatment for Pancreatic Neuroendocrine Tumors is surgery  [4] and they can be safely 
resected. Malignant cases should be treated with aggressive radical surgery to achieve complete 
tumor resection [5] but in well-differentiated lesion we can perform a procedure preserving most of 
the parenchyma, like partial pancreatectomy. 
 
2. Case report 
A 58 years old woman was admitted to our Emergency Department for epigastric pain, nausea and 
weight loss. The patient had diabetes mellitus and arterial hypertension. Physical examination 
revealed nothing pathological and routine laboratory analyses (WBC, PCR) were normal. 
Abdominal US revealed a15×13 mm lesion of the pancreatic corpus with hypoechoic patterns and 
positive Doppler evaluation. Abdominal CT described a microcystic lesion of 19 mm, with 
disomogenic matter and positive enhancement in arterial phase. Bio-humoral evaluation of 
Chromogranin A, Glucagon, carcinoembryonic antigen, carbohydrate antigen 19-9 and ENS 
(Enolase Neuronal Specific) was in range. During EUS (Endoscopic UltraSound) an intrapancreatic 
hypoechoic lesion without lymphadenopathy was observed. Biopsy revealed a hypercellular lesion 
with papillar pattern, muciparous secretion and nuclear anomalies. Explorative laparotomy revealed 
a capsulated lesion of the pancreatic corpus without vascular invasion. There was no evidence of 
intra-abdominal metastases. We performed a parenchyma preserving meso-pancreatectomy (MP). 
Upon exposure the lesion was all intrapancreatic and during intraoperative Ultrasound no vascular 
invasion was confirmed. The pancreas was released by posterior vessels and the parenchyma was 
divided at 1 cm proximally and distally from the lesion. The anatomical preparation was submitted 
to a pathologist that confirmed the lesion and declared that the margins were cleared. 
Reconstruction was accomplished with anastomosis between the ileus and the tail of the pancreas, 
performed with absorbable monofilament suture; we performed a Roux-en-Y with 
pancreaticojejunostomy reconstruction to distal pancreatic stump. A pancreatic stent was inserted in 
Wirsung's stump tract and the head tract was clamped. We placed a two tube drain in para-
anastomotic position. A glucagon-producer endocrine tumor with uncertain biological behavior was 
diagnosed at the time of pathologic evaluation. On immunohistochemical evaluation Chromogranin 
A, Cytokeratin and Glucagon levels were positive and Ki67 mutation percentage was 1%. After 
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surgery an antibiotic therapy was set. On the 7th postoperative day a pancreatic fistula (Drainage 
Amy=15.000) was detected from the head section, that was solved with a conservative approach, 
parenteral nutrition, antibiotic and analgesic therapy. The nasogastric tube was removed on the 3rd 
postoperative day and drains on the 27th and 30th day. The patient was discharged on the 36th 
postoperative day. 
A CT scan was performed on the 90th postoperative day and after 6 and 12 months with no 
evidence of complications. 
The patient has been followed-up as an out-patient for 5 years and she has no sign of local 
recurrence or distant metastases. 
 
3. Discussion 
Pancreatic endocrine tumors represent a heterogeneous group with varying tumor biology and 
prognosis. These neoplasms are classified as functional if they are associated with a hormone-
related clinical syndrome caused by hormone release from the tumor, or non-functional if the tumor 
is not associated with a hormone-related clinical syndrome [6]. Glucagonoma is a slow-growing 
alpha-cell tumor of the pancreatic islets of Langerhans. It is characterized by necrolytic migratory 
erythema (NME), hypoaminoacidemia, cheilosis and diabetes mellitus that is found in 80% of 
patients with glucagonoma syndrome [7], [8] and [9]. 
A glucagonoma may appear as a benign and localized alpha-cell adenoma but at least 50% of cases 
will have metastatic disease when diagnosed [4]. Disease progression is often slow even in the 
presence of metastases, and the patients may need sequential excision of lymph node or liver 
metastases during a long disease course, with often 5 years or more between recurrent lesions. In 
literature the reported 10-year survival is about 50% [10]. The optimal treatment for glucagonoma 
is surgery, but 50% of the tumors have metastasized at time of diagnosis [4] and [11]. 
We performed a meso-pancreatectomy because, according to literature, we believe that the 
parenchymal preservation is essential and appropriately selected patients will benefit from extended 
central pancreatectomy because of the maintenance of endocrine and exocrine function [12]. 
Furthermore, in selected cases of central pancreatic lesion, central pancreatectomy is associated 
with less perioperative morbidity and mortality than extended classic resection [13] and [14]. In 
Adham's series, central pancreatectomy led to effective preservation of both cephalic and distal 
pancreatic remnants without a significant increase in postoperative morbidity compared with 
conventional pancreatectomy [15] and [16]. Furthermore, long-term local recurrence after extended 
central pancreatectomy is similar to the recurrence rates after extended classic resection [13] and 
[17]. 
In our case we assisted at the onset of a fistola; in literature pancreatic fistula and delayed gastric 
emptying are the most prevalent complications of pancreatectomy but in the majority of cases they 
can be managed by conservative measures [3]. 
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4. Conclusion 
In selected cases, the MP is a great technique when performed by experienced hands. Parenchymal 
preservation, in order to avoid endocrine and exocrine pancreatic insufficiency, remains a critical 
decision for the patients outcome. 
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